Related Experiment Video
Updated: Jun 12, 2025
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
35.1K
Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization
Long Cheng1,2,3, Zeming Qiu1,2,3, Xuewu Wu1,2,3
1Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, China.
Discover Oncology
|September 17, 2024
Summary
This study identified nine plasma proteins linked to increased prostate cancer (PCa) risk and four to decreased risk. Several proteins show potential as drug targets for PCa, with some influenced by lifestyle factors.
Area of Science:
- Proteomics
- Genetics
- Oncology
Background:
- Plasma proteins are crucial for identifying cancer diagnostic and therapeutic targets.
- Understanding causal links between plasma proteins and prostate cancer (PCa) is essential.
Purpose of the Study:
- To investigate causal associations between plasma proteins and PCa.
- To explore downstream effects of plasma proteins and identify upstream modulators.
Main Methods:
- Proteome-wide Mendelian randomization was employed to assess causal effects.
- Summary-statistics-based Mendelian Randomization (SMR) and colocalization analyses identified gene-PCa associations.
- Phenome-wide and lifestyle factor analyses explored downstream phenotypes and upstream modulators.
Main Results:
- Nine proteins showed a positive genetic association with PCa risk; four showed an inverse association.
- ZG16B, PEX14, and NAPG were identified as potential PCa drug targets.
- Ten plasma proteins were found to be potentially modulated by lifestyle factors.
Conclusions:
- Plasma proteins are genetically associated with PCa risk.
- Identified proteins represent potential therapeutic targets for PCa.
- Findings enhance understanding of PCa's molecular basis, prevention, and treatment.
